Bayer and CureVac to collaborate on COVID-19 vaccine candidate

pharmafile | January 8, 2021 | News story | Medical Communications Bayer, COVID-19, Vaccine 

Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 vaccine candidate CVnCoV.

Under the parties’ collaboration and services agreement, Bayer will support the further development, supply, and key territory operations of CureVac´s coronavirus jab.

CureVac commenced Phase IIb/III trials for its vaccine candidate last month, after ramping up its European manufacturing network in November.

CureVac will be the Marketing Authorisation Holder for the product. Bayer will support CureVac with country operations within the EU and selected additional markets, but holds further options to become Marketing Authorisation Holder in other markets outside of Europe.

The companies plan to supply hundreds of millions of CVnCoV doses globally once approvals are granted.

Stefan Oelrich, Member of the Board of Management at Bayer and President of the Bayer’s Pharmaceuticals Division, said: “The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate.

“We are highly committed to making our capabilities and networks available to help end this pandemic.”

Darcy Jimenez

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

Latest content